Leap Investments’s GenMark Diagnostics, Inc GNMK Stock Holding History

Leap Investments’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-18,600	Closed	-$121K	–	546
2019 Q2	$121K	Buy	+18,600	New	+$131K	0.16%	193

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Leap Investments's GNMK Position: Q3 2019 in Review

Leap Investments sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2019, closing a stake of 18,600 shares — an estimated $121K sold.

Leap Investments first reported a position in GNMK in Q2 2019 and held it in 1 quarter. The position peaked at $121K in Q2 2019. 110 funds tracked by Wall St. Rank hold GNMK as of Q3 2019.

Leap Investments reported no remaining GenMark Diagnostics, Inc position as of Q3 2019 after selling out during the quarter.
Leap Investments sold 18,600 GenMark Diagnostics, Inc shares in Q3 2019, an estimated $121K.
Leap Investments first reported a position in GenMark Diagnostics, Inc in Q2 2019 and held it in 1 quarter.
Leap Investments's GenMark Diagnostics, Inc position peaked at $121K in Q2 2019.
110 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2019.

Based on Leap Investments's 13F filing for Q3 2019, filed 13 Nov 2019.